» Articles » PMID: 29238203

Expression Patterns of MicroRNA-329 and Its Clinical Performance in Diagnosis and Prognosis of Breast Cancer

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2017 Dec 15
PMID 29238203
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

This study was aimed to assess the expression and clinical performance of microRNA-329 (miR-329) in breast cancer. We recruited 134 breast cancer patients and 70 healthy volunteers for this study. MiR-329 expression was estimated by quantitative real-time polymerase chain reaction. A receiver operating characteristic assay was performed to evaluate the diagnostic value of serum miR-329. In addition, the prognostic significance of miR-329 was evaluated through Kaplan-Meier survival and Cox regression analyses. According to quantitative real-time polymerase chain reaction, miR-329 expression was downregulated in cancerous samples compared with healthy and normal controls (<0.01), and its expression in serum specimens positively correlated with its expression in tissue samples (R=0.493, <0.001). The decreased expression of miR-329 correlated with lymph node metastasis (=0.015) and TNM stage (=0.003). A receiver operating characteristic curve with an area under the curve of 0.932 was constructed, indicating the high diagnostic accuracy of miR-329. From the survival and multivariate Cox assays, we found that downregulated miR-329 expression was associated with poor overall survival (log-rank <0.001) and served as an independent prognostic factor (hazard ratio =2.987, 95% CI =1.681-5.308, and <0.001). In silico analysis using The Cancer Genome Atlas confirmed that miR-329 expression was lower in breast cancer cases compared with normal controls (<0.001) and could be an efficient biomarker for cancer patients. Down-regulated miR-329 expression was an effective diagnostic and prognostic biomarker, which could be used for targeted therapy in patients with breast cancer.

Citing Articles

Global MicroRNA Profiling of HSV-1 Infected Cornea Identifies miR-329 as a Novel Regulator of Virus Infection.

Sharma P, Naqvi R, Borase H, Kapoor D, Valverde A, Capistrano K Invest Ophthalmol Vis Sci. 2025; 66(2):61.

PMID: 39992671 PMC: 11878248. DOI: 10.1167/iovs.66.2.61.


ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See!.

Chamandi G, El-Hajjar L, Kurdi A, Le Bras M, Nasr R, Lehmann-Che J Biomedicines. 2023; 11(8).

PMID: 37626796 PMC: 10452617. DOI: 10.3390/biomedicines11082300.


The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies.

Quirico L, Orso F Cancer Drug Resist. 2022; 3(2):117-139.

PMID: 35582611 PMC: 9090592. DOI: 10.20517/cdr.2019.103.


Emerging Evidence of the Functional Impact of the miR379/miR656 Cluster (C14MC) in Breast Cancer.

McCarthy E, Dwyer R Biomedicines. 2021; 9(7).

PMID: 34356891 PMC: 8301419. DOI: 10.3390/biomedicines9070827.


Differential expression of miR-1297, miR-3191-5p, miR-4435, and miR-4465 in malignant and benign breast tumors.

Mosapour A, Tehrani F, Atri M Iran J Basic Med Sci. 2020; 23(8):1045-1052.

PMID: 32952951 PMC: 7478249. DOI: 10.22038/ijbms.2020.44581.10421.


References
1.
Johnson R, Chien F, Bleyer A . Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA. 2013; 309(8):800-5. DOI: 10.1001/jama.2013.776. View

2.
Kirsh V, Chiarelli A, Edwards S, OMalley F, Shumak R, Yaffe M . Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer Inst. 2011; 103(12):942-50. DOI: 10.1093/jnci/djr138. View

3.
Yu J, Jin L, Jiang L, Gao L, Zhou J, Hu Y . Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer. Anticancer Agents Med Chem. 2015; 16(4):424-31. DOI: 10.2174/1871520615666150716110406. View

4.
Luo M, Shen D, Zhou X, Chen X, Wang W . MicroRNA-497 is a potential prognostic marker in human cervical cancer and functions as a tumor suppressor by targeting the insulin-like growth factor 1 receptor. Surgery. 2013; 153(6):836-47. DOI: 10.1016/j.surg.2012.12.004. View

5.
Chen Z, Tang Z, He Y, Liu L, Li D, Chen X . miRNA-205 is a candidate tumor suppressor that targets ZEB2 in renal cell carcinoma. Oncol Res Treat. 2014; 37(11):658-64. DOI: 10.1159/000368792. View